MAGNASENSE Aktie

 

Das Instrument 52Q SE0014401121 MAGNASENSE AB EQUITY wird ex Kapitalmassnahme gehandelt am 17.04.2025 The instrument 52Q SE0014401121 MAGNASENSE AB EQUITY is traded ex capital adjustment on 17.04.2025...

Das Instrument 52Q SE0014401121 MAGNASENSE AB EQUITY wird ex Kapitalmassnahme gehandelt am 03.03.2025 The instrument 52Q SE0014401121 MAGNASENSE AB EQUITY is traded ex capital adjustment on 03.03.2025...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, JAPAN, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD NOT BE IN COMPLIANCE WITH APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE REGISTRATION OR SIMILAR MEASURES. PLEASE SEE ”IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. The board of directors of AegirBio AB (“AegirBio” or the “Company”) has today, based on the...

Lund May 29, 2024. AegirBio's CEO Marco Witteveen willparticipate in SalivaDirect's 3rd Annual Conference on June 5-7 at The Darcy Hotel in Washington, DC This prestigious 3-day event is tailored to foster dynamic discussions and collaborations, offering an ideal platform to exchange innovative ideas with some of the most brilliant minds in the industry. As attendee, AegirBio is eagerly anticipating the opportunity to gain insights from esteemed members of the company's network and renowned leaders in the diagnostic world. "We are excited to participate in SalivaDirect's 3rd Annual...

Leading Diagnostics Innovator Advances Accessibility Project for Multiplex Testing AegirBio AB, a forefront leader in saliva-based diagnostics solutions, proudly announces the successful completion of an additional Milestone  in its participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program. AegirBio's phase 1 award, focusing on an accessibility project for multiplex testing, positions the company at the forefront of digital self-test platform development with potential milestone-based payments of up to USD 1.2 million. The RADx® Tech...